WHWK — Whitehawk Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422142 ·
Last close
$3.76
Market Cap
$214.35M
52W High
$5.49
52W Low
$1.82
ADV30
311,507
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -18,109,000 | -16,640,000 | 193,994,000 | 85,234,000 | 11,069,000 |
| Mar 2026 | 0 | 0 | -23,522,000 | -22,194,000 | 127,231,000 | 34,790,000 | 11,056,000 |
| Dec 2025 | 0 | 0 | -24,887,000 | -23,251,000 | 150,830,000 | 37,568,000 | 14,519,000 |
| Sep 2025 | 0 | 0 | -19,546,000 | -17,746,000 | 167,017,000 | 37,931,000 | 9,849,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,349,000
Investing CF
$-72,218,000
Financing CF
$81,865,000
CapEx
$-738,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-392,084,000
Inventory
$0
Receivables
$0
ST Investments
$104,748,000
EBIT TTM
$-82,628,000
Pretax Income TTM
$-79,831,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-86,056,000
Free Cash Flow
$-43,611,000
Enterprise Value
$44,325,032
Total Cash
$189,982,000
Total Debt
$0
Shares Out
57,009,010
Trailing EPS
$-1.21
Book Value
$2.46
ROE
-45.0%
ROA
-28.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,145,000 | -114,400,000 | -20,596,000 | 150,830,000 | 14,519,000 | 136,311,000 | -97,433,000 |
| Dec 2024 | 25,983,000 | -64,820,000 | -63,691,000 | 70,319,000 | 17,841,000 | 52,478,000 | -59,550,000 |
| Dec 2023 | 24,354,000 | -71,933,000 | -65,765,000 | 132,423,000 | 27,228,000 | 105,195,000 | -59,663,000 |
| Dec 2022 | 15,216,000 | -58,957,000 | -60,513,000 | 184,237,000 | 25,859,000 | 158,378,000 | -49,640,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.99
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.76 · call volume: 3 · put volume: 30
Expected Move to 2026-10-16:
±$2.45
(65.16%) —
implied range
$1.31 –
$6.21
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELDN | Eledon Pharmaceuticals, Inc. | $214.53M | $2.64 | — |
| ADAG | Adagene Inc. | $214.86M | $3.20 | — |
| RNAC | Cartesian Therapeutics, Inc. | $218.14M | $7.21 | — |
| FHTX | Foghorn Therapeutics Inc. | $209.04M | $3.52 | — |
| KROS | Keros Therapeutics, Inc. | $223.65M | $11.28 | — |
News headlines (Yahoo Finance, 1h cache)
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
2026-09-14 01:30 · Yahoo
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?
2026-08-28 16:00 · Yahoo
Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know
2026-08-26 13:55 · Yahoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 11:05 · Yahoo
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
2026-07-07 12:00 · Yahoo
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
2026-06-10 18:22 · Yahoo
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
2026-05-30 18:30 · Yahoo
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
2026-05-28 20:05 · Yahoo
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
2026-05-20 12:00 · Yahoo
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
2026-08-13 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.